DarkIris Inc. Announces 16 for 1 Share Consolidation

Move ensures continued compliance with Nasdaq while positioning the Company to execute its global AI-generated content (AIGC) expansion and synergistic acquisitions

HONG KONG, May 07, 2026 (GLOBE NEWSWIRE) — DarkIris Inc. (Nasdaq: DKI) (the “Company” or “DarkIris”), a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games through various third-party digital storefronts, today announced that it will effect a share consolidation of its Class A ordinary shares of par value US$0.0001 each and Class B ordinary shares of par value US$0.0001 each at a ratio of 1-for-16, effective on May 11, 2026 (the “Share Consolidation”). The Company’s Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on May 11, 2026. Upon the market opening on May 11, 2026, the Company’s Class A ordinary shares will continue to trade on The Nasdaq Capital Market under the symbol “DKI” with the new CUSIP number G2657S111.

Prior to the Share Consolidation, 26,361,114 Class A ordinary shares are issued and outstanding. As a result of the Share Consolidation, every 16 shares (or part thereof) will be combined into one (1) share, with fractional shares rounded up to the next whole share, and approximately 1,647,570 Class A ordinary shares will be issued and outstanding after the Share Consolidation. The Company is authorized to issue 31,250,000 number of shares, divided into two Classes consisting of: (i) 28,125,000 Class A ordinary shares of par value US$0.0016 each and (ii) 3,125,000 Class B ordinary shares of par value US$0.0016 each. All outstanding stock options, warrants and other rights to purchase the Company’s Class A ordinary shares will be adjusted proportionately as a result of the Share Consolidation.

Upon the effectuation of the Share Consolidation, shareholders holding shares through a bank, broker or other nominee will have their shares automatically adjusted to reflect the Share Consolidation. Beneficial holders may contact their bank, broker or nominee for more information. Please direct any questions to your broker or the Company’s transfer agent, Transhare Corporation, by calling +1 303-662-1122.

Management Commentary

Mr. Zhifang Hong, Chairman of the Board of DarkIris, commented: “This share consolidation is a critical step to ensure our continued compliance with Nasdaq’s listing standards, which serves as the foundation for DarkIris’s next phase of growth. By solidifying our Nasdaq presence and optimizing our capital structure, we are unlocking significant advantages, including enhancing our appeal to a broader base of institutional investors. Armed with the resources from our recently closed $3.8 million private investment in public equity (PIPE) financing and $800,000 content acquisition of premium film and television intellectual properties, our management team is fully focused on driving business development. Moving forward, we are actively evaluating opportunities to acquire high-quality global assets across gaming, film, AI core technologies, and user platforms. Our goal is to selectively pursue synergistic acquisitions that will complete our ‘Pan-Entertainment Cultural Ecosystem Loop’ and deliver sustainable, long-term value to our shareholders.”

About DarkIris Inc.

DarkIris Inc. is a comprehensive technology enterprise based in Hong Kong, engaged in the development, publishing and operating of mobile digital games through various third-party digital storefronts. The Company conducts its business through its subsidiaries, Quantum Arts Co., Limited and Hongkong Stellar Wisdom Co., Limited. The Company’s activities include game design, programming and graphics, as well as the distribution and operation of mobile games across multiple platforms. DarkIris leverages (i) the innovative, creative and technical expertise of Hong Kong’s gaming industry community, and (ii) the multicultural environment and diverse interests of mobile game players in the regions. The Company’s goal is to create and promote a broader array of engaging, immersive, and captivating mobile game genres for a global audience. The Company is committed to consistently showcasing exceptional strength and unique allure across diverse gaming sectors, leading the way in pioneering advancements within the industry. For more information, please visit the Company’s website: www.darkiris.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, the Company’s future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions, the Company’s ability to comply with Nasdaq continued listing standards and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

DarkIris Inc.

Investor Relations Department
Email: [email protected]

Ascent Investor Relations LLC

Tina Xiao
Phone: +1 646-932-7242
Email: [email protected]



10th Capital Link Maritime Leaders Summit – A Posidonia Conference Program Event

Monday, June 1, 2026 – Athenaeum Intercontinental Athens

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) — The 10th Capital Link Maritime Leaders Summit – Greece will take place on Monday, June 1, 2026, as an in-person event at the Athenaeum Intercontinental Athens. Held every two years, the Forum is organized in partnership with DNV and in cooperation with NASDAQ and NYSE, and is part of the Posidonia Week Conference Program.

Attracting more than 1,000 delegates, the Summit brings together the leadership of Greek shipping alongside a global audience of shipowners, institutional investors, financiers, regulators, industry participants and international media who travel to Athens specifically to engage with the Greek maritime ecosystem. As one of the most impactful events of Posidonia Week, it offers a unique platform where industry leaders share insights on critical market dynamics and the future direction of global shipping.

The agenda spans tanker, container, and dry bulk markets, geopolitics, global trade, energy transition, and technological innovation, while also highlighting the current and next generation of Greek shipping leadership. With its high-caliber speaker lineup and global reach, the Forum provides a rare opportunity to engage directly with key maritime and investment decision-makers in one setting.


REGISTRATION:
   Please register here:
https://forums.capitallink.com/shipping/2026analyst/signup.html

AGENDA TOPICS

Welcome Remarks:

  • Mr. George M. Teriakidis, Regional Manager for Southeast Europe, Maritime – DNV
  • Mr. Nicolas Bornozis, President – Capital Link

Keynote Opening Remarks:

  • Minister Vasilis Kikilias, Minister of Maritime Affairs and Insular Policy – Hellenic Republic

TANKER MARKETS IN MOTION: ENERGY SHIFTS, TRADE REALIGNMENT, & INVESTMENT STRATEGY

Moderator:
Mr. Keith Billotti, Partner – Seward & Kissel LLP
Panelists:

  • Mr. Antonis Kanellakis, Executive Director – Alpha Bulkers / Pantheon Tankers / Alpha Gas
  • Mr. Jerry Kalogiratos, CEO – Capital Tankers Corp. (EGO: CAPT)
  • Mr. Yiannis Procopiou, CEO – Centrofin Management Inc.
  • Mr. Svein Moxnes Harfjeld, President & Chief Executive Officer & Member of the Board of Directors – DHT Holdings, Inc. (NYSE: DHT)
  • Mr. Pankaj Khanna, CEO – Heidmar Maritime Holdings Corp. (NASDAQ: HMR)

DRY BULK AT AN INFLECTION POINT: SUPPLY, DEMAND, & CORPORATE STRATEGY

Moderator: Ms. Sofia Kalomenides, Partner – Europe Central Capital Markets Leader – EY
Panelists:

  • Ms. Semiramis Paliou, Director & CEO – Diana Shipping Inc. (NYSE: DSX); Chairperson – HELMEPA & INTERMEPA
  • Mr. Costas Delaportas, CEO – DryDel Shipping
  • Mr. John Dragnis, CEO – Goldenport Group
  • Mr. Polys Hajioannou, CEO – Safe Bulkers, Inc. (NYSE: SB); President – Cyprus Union of Shipowners (CUS)
  • Mr. Stamatis Tsantanis, Chairman & Chief Executive Officer – Seanergy Maritime Holdings Corp. (NASDAQ: SHIP); Founder, Chairman & Chief Executive Officer – United Maritime Corporation (NASDAQ: USEA)

PRESENTATION

  • Mr. John McDonald, Chairman & Chief Executive Officer – ABS

SHIPPING AS THE BACKBONE OF GLOBAL TRADE – SAFEGUARDING SUPPLY CHAINS AMID GEOPOLITICS, RISKS, & DISRUPTION

Moderator: Ms. Han Deng, Partner – Reed Smith LLP
Panelists:

  • Mr. Aristides J. Pittas, Chairman & CEO – Euroseas Ltd. (NASDAQ: ESEA); EuroDry Ltd. (NASDAQ: EDRY); Euroholdings Ltd. (NASDAQ: EHLD)
  • Mr. George Youroukos, Executive Chairman – Global Ship Lease, Inc. (NYSE: GSL)
  • Mr. Andy McKeran, Chief Growth Officer – Lloyd’s Register
  • Mr. René Kofod-Olsen, Group CEO – V.Group

GLOBAL CAPITAL MARKETS & SHIPPING: THE ROLE OF EURONEXT ATHENS

1X1 DISCUSSION WITH

  • Mr. Mathieu Caron, Group Head of Primary Markets, Member of the Executive Committee – Euronext
  • Mr. Yianos Kontopoulos, CEO – Euronext Athens

KEYNOTE SESSION

1X1 DISCUSSION WITH

  • Mr. Arsenio Dominguez, Secretary General – International Maritime Organization (IMO)
  • Mr. Knut Ørbeck-Nilssen, Group President & CEO – DNV

INNOVATION & TECHNOLOGY: ENABLING THE FUTURE OF GLOBAL SHIPPING

Moderator: Ms. Anthi Miliou, Maritime Commercial Director – Lloyd’s Register
Panelists:

  • Mr. Brian Matthews, Founder & CEO – AMPERA
  • Dr. Konstantinos Kyriakopoulos, CEO & Co-Founder – DeepSea Technologies
  • Mr. Yarden Gross, CEO & Co-Founder – Orca AI
  • Mr. Nicholas K. Notias, CEO – SteelShips LLC
  • Ms. Marina Hadjipateras, Founder & Managing Partner – TMV

GREEN SHIPPING DEBATE: ALIGNING REGULATION, REALITY AND RESULTS

Moderator: Mr. Paolo Moretti, CEO – RINA SERVICES S.p.A
Panelists:

  • Ms. Dorothea Ioannou, CEO – American P&I Club
  • Mr. Andreas Hadjipetrou, CEO – Columbia Group
  • Mr. Polys Hajioannou, President – Cyprus Union of Shipowners (CUS); CEO – Safe Bulkers, Inc. (NYSE: SB)
  • Mr. Alex Hadjipateras, COO – Dorian LPG Ltd. (NYSE: LPG); Managing Director – Dorian LPG Management Corp.
  • Ms. Ioanna Procopiou, Managing Director – Prominence Maritime; President Designate – BIMCO

SHIPPING AT CROSSROADS: GEOPOLITICS, GLOBAL MARKET SHIFTS, & STRATEGIC POSITIONING

Moderator: Ms. Cristina Saenz de Santa Maria, CEO Maritime – DNV
Panelists:

  • Captain Abdulkareem Al Masabi, CEO – ADNOC Logistics & Services (DH: ADNOCLS)
  • Dr. John Coustas, Chairman, President & CEO – Danaos Corporation (NYSE: DAC)
  • Dr. Anil Sharma, Founder & CEO – GMS & Lila Global
  • Mr. Harry Vafias, Founder – Stealthgas (GASS) / Imperial Petroleum (IMPP) / C3iS inc (CISS)
  • Dr. Nikolas P. Tsakos, Founder & CEO – TEN Ltd. (NYSE: TEN); Chairman – INTERTANKO (2014-2018)

BRIDGING LEGACY, LEADERSHIP & TRANSFORMATION – SHAPING THE NEXT CHAPTER OF GREEK SHIPPING

Moderator: Ms. Paillette Palaiologou, M&O East Europe, Mediterranean Sea, Middle East, India & Africa (EMA) Senior Vice President – Bureau Veritas
Panelists:

  • Ms. Marielena Procopiou, Founder & Chief Executive Officer – Delos Navigation and Akrotiri Tankers
  • Mr. Diamantis Pateras, Deputy CFO – Contships Management Inc.
  • Ms. Eirini Pitta, Investor Relations Officer – Euroseas Ltd. (NASDAQ: ESEA); EuroDry Ltd. (NASDAQ: EDRY); Management Consultant – Eurobulk Ltd.;
  • Ms. Amalia Miliou-Theocharaki, Deputy Managing Director – TEO Shipping Corporation

NAVIGATING THE MARKET – STRATEGY, SCALE, & SHIPPING CYCLES

Moderator: Ms. Dora Mace-Kokota, Partner, International Head – Maritime, Trade and Offshore and Managing Partner, Greek Office – Stephenson Harwood
Speakers:

  • Mr. Petros Pappas, CEO & Director – Star Bulk Carriers Corp. (NASDAQ: SBLK)
  • Mr. George Economou, Founder – TMS Group

SHIPPING & THE GLOBAL ENERGY LANDSCAPE

Moderator: Mr. George Paleokrassas, Senior Partner – Watson Farley & Williams
Panelists:

  • Ms. Maria Angelicoussis, CEO – Angelicoussis Group
  • Eng. Ahmed Ali Alsubaey, CEO & Board Member – Bahri Group
  • Mr. Evangelos Marinakis, Founder & Chairman – Capital Maritime & Trading Corp.
  • Mr. George Prokopiou, Founder – Dynacom Tankers Management Ltd. / Dynagas Ltd. / Sea Traders S.A.


THE FORUM IS ORGANIZED:


IN PARTNERSHIP WITH: DNV
IN COOPERATION WITH: NASDAQ • NYSE
GLOBAL LEAD SPONSOR: TEN Ltd.
GLOBAL GOLD SPONSORS: Columbia Group • EY
GLOBAL SPONSORS: ABS • Bureau Veritas • GMS • Lila Global • Seward & Kissel LLP • Stephenson Harwood • Watson Farley & Williams
SPONSORS: The American P&I Club • AMPERA • DeepSea • Euronext • Lloyd’s Register • Orca AI • ReedSmith • RINA • V. Group
SPOTLIGHT PODCAST SPONSORS: Best Oasis • Columbia Group • DHT • RMS • ShipIn • SPM Shipping • Wilhelmsen
SUPPORTING SPONSORS: Capital Clean Energy Carriers Corp. • Danaos Corporation • DHT Holdings, Inc. • Diana Shipping Inc. • Dorian LPG Ltd. • Dynacom • Dynagas LNG Partners LP • EuroDry Ltd. • Euroholdings Ltd. • Euroseas Ltd. • Flott & Co. PC • Global Ship Lease, Inc. • Heidmar Maritime Holdings Corp. • LSEG Data & Analytics • Optima Shipping Services • Safe Bulkers, Inc. • Seanergy Maritime Holdings Corp. • Sea Traders S.A. • Singhai Marine Services • Splash MMP • Star Bulk Carriers Corp. • United Maritime Corporation

BREAKFAST SPONSORS: Castor Maritime Inc. • Toro Corp.
COFFEE SPONSORS: Franman • Dimello • Papadopoulos
Wi-Fi SPONSOR: ICBC
BAGS SPONSOR: The Marshall Islands Registry

SUPPORTING ORGANIZATIONS: BCA College • Association of Banking and Financial Executives of Hellenic Shipping • Hellenic Chamber of Shipping • Greek Shipping Co-operation Committee • HSA • InterManager • Athens University of Economics and Business, MSc in International Shipping, Finance and Management • Sailors’ Society • SEA – LNG

MEDIA PARTNERS: All About Shipping • The Business Events Calendar • efoplistesnews.gr • Efoplistis Shipping Magazine • Kerkyra Publications – Economia • ELNAVI • The Japan Maritime Daily • KAIJI PRESS • Marine Circle • Maritime Executive • Maritimes.gr • Nafs Green Group • Naftika Chronika • Robban Assafina • Shipping Finance • Xinde Marine News

FOR MORE INFORMATION

Please visit: https://capitallink.com/forums/10th-capital-link-maritime-leaders-summit-greece/?section=overview

Please contact:

NEW YORK // Olga Bornozi, Managing Director at [email protected] & Eleni Bej, Chief Operating Officer, at [email protected] – Tel. : +1 (212) 661-7566

ATHENS // Anna Wichmann, Business Development Manager, at [email protected] & Athena Kosmadaki, Marketing & Media Relations Manager, at [email protected] – Tel.:  +30 210 6109 800.

For sponsorship opportunities please contact: Please contact Nicolas Bornozis, President – Olga Bornozis, Managing Director & Anny Zhu, Managing Director at [email protected] – Tel.: +1 (212) 661-7566.


Or visit:


https://capitallink.com/


https://capitallink.com/forums



ORGANIZERS



Founded in 1995, Capital Link is a New York based investor relations, financial communications and advisory firm with a strategic focus on the maritime, commodities and energy sectors, MLPs, as well as Closed-End Funds and ETFs. In addition, Capital Link organizes 18 high quality Investment Forums, webinars and podcasts, focusing on maritime transportation and U.S. investment products in 11 countries in the United States, Europe and Asia, in key industry centers, such as New York, London, Oslo, Hamburg, Athens, Limassol, Shanghai, Singapore, Tokyo, Hong Kong and Dubai, all of which are known for combining rich educational and informational content with unique marketing and networking opportunities. Capital Link is a data partner of the Baltic Exchange. Based in New York City, Capital Link has presence in London, Athens & Oslo.



Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 14, 2026, to review its financial results for the quarter ended March 31, 2026 and to provide a company update.

To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 2531472. The live webcast can be accessed under “Presentations, Events & Webcasts” in the Investors section of the company’s website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. The webcast will be archived in the same section of the company’s website and available for replay until May 28, 2026.

About Daré Bioscience

Daré Bioscience is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, Daré is working to close critical gaps in care using science that serves her needs.

For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to real, evidence-based solutions continues to lag. Daré was founded to change that. As a female-led health biotech company, Daré is accelerating the development of credible, science-based solutions that meet the high standards of clinical rigor – randomized, controlled trials; validated endpoints; peer-reviewed publications; and current Good Manufacturing Practice (cGMP) requirements.

To learn more about Daré’s mission to deliver differentiated therapies for women and its innovation pipeline, please visit www.darebioscience.com.

Daré Bioscience leadership has been named on the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma and Daré’s CEO has been honored as one of Fierce Pharma’s Most Influential People in Biopharma for Daré’s contributions to innovation and advocacy in the women’s health space.

Daré may announce material information about its finances, products and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, products and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.

Contacts:

Daré Bioscience Investor Relations

[email protected]

Source: Daré Bioscience, Inc.



Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for topline results in August 2026

LONDON–(BUSINESS WIRE)–
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2026, and provided an update on recent business achievements.

“The Silence team continues to advance research supporting the broad potential of our mRNAi GOLD™ platform, and we remain well positioned as we approach a significant company milestone,” said Iain Ross, Chairman and Interim Principal Executive Officer at Silence. “With Phase 2 topline results in PV expected this August, our team remains focused on progressing divesiran and delivering long‑term value for patients and shareholders.”

Business Highlights

Divesiran: First-in-class siRNA for PV

  • SANRECO Phase 1 study abstract accepted for poster presentation at the European Hematology Association (EHA) 2026 Annual Congress taking place June 11-14, 2026.

    • Divesiran, A Novel GalNac Conjugated SiRNA, Reduces Phlebotomies, Improves Iron Stores and Symptoms in Polycythemia Vera Patients in SANRECO Phase 1 Study

      Abstract #PF886, Poster Session 1 on Friday, June 12 (6:45-7:45 p.m. EST)

  • SANRECO Phase 2 double-blind, placebo-controlled study evaluating divesiran 6 mg (Q6W and Q12W dosing intervals) in 48 phlebotomy-dependent PV patients is ongoing with topline results on-track for August 2026.

SLN312 (AZD1705): Phase 1 siRNA with a competitive profile for dyslipidemia

  • Phase 1 study abstract accepted for late-breaking oral presentation at the European Atherosclerosis Society (EAS) Congress taking place May 24-27, 2026.

    • Liver-Targeted ANGPTL3 Silencing with AZD1705 Lowers Atherogenic Lipoproteins: Preclinical Validation and Phase 1 Results

      Abstract #1610, Late Breaker Clinical Abstracts Session on Tuesday, May 26 (3:45–5:15pm EST)

First Quarter 2026 Financial Results

  • Cash Position: Cash, cash equivalents, and short-term investments were $70.1 million as of March 31, 2026. This includes cash and cash equivalents of $5.7 million and short-term investments of $64.4 million.
  • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025.
  • R&D Expenses: Research and development (R&D) expenses were $9.1 million for the three months ended March 31, 2026, compared to $20.8 million for the three months ended March 31, 2025. The decrease is largely due to the zerlasiran Phase 3 readiness being completed in 2025.
  • G&A Expenses: General and administrative (G&A) expenses were $7.0 million for the three months ended March 31, 2026, compared to $7.7 million for the three months ended March 31, 2025.
  • Net Loss: Net loss was $15.0 million, or $0.11 basic and diluted net loss per share for the three months ended March 31, 2026, compared to a net loss of $28.5 million, or $0.20 basic and diluted net loss per share for the three months ended March 31, 2025.
  • Total outstanding shares were 141,703,840 ordinary shares (including shares in the form of American Depositary Shares) as of March 31, 2026.

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit https://www.silence-therapeutics.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the Company’s business strategy and plans, including the Company’s clinical development activities and timelines; the potential therapeutic benefits of the Company’s product candidates; the anticipated timing of initial topline and future results from the SANRECO Phase 2 trial; the Company’s ability to deliver long-term value; and the Company’s ability to advance additional candidates from its mRNAi GOLD™ platform. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the company’s ability to obtain regulatory approval of and successfully commercialize its product candidates either on its own or with potential partners; any undesirable side effects or other properties of the company’s product candidates; the company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Silence Therapeutics plc

Condensed Consolidated Balance Sheets

(Unaudited, in thousands, except share and per share data)

 

 

 

 

 

 

 

 

March 31, 2026

 

December 31, 2025

Current assets

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

$

5,657

 

 

$

11,277

 

Short-term investments

 

 

 

64,421

 

 

 

73,837

 

R&D benefit receivable

 

 

 

22,216

 

 

 

22,007

 

Other current assets

 

 

 

10,558

 

 

 

11,537

 

Trade receivables

 

 

 

 

 

 

 

Total current assets

 

 

 

102,852

 

 

 

118,658

 

Property, plant and equipment

 

 

 

1,396

 

 

 

1,581

 

Operating lease right-of-use assets

 

 

 

142

 

 

 

167

 

Goodwill

 

 

 

10,358

 

 

 

10,621

 

Other intangible assets

 

 

 

248

 

 

 

288

 

Other long-term assets

 

 

 

127

 

 

 

127

 

Total assets

 

 

$

115,123

 

 

$

131,442

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

Contract liabilities

 

 

$

 

 

$

(168

)

Trade and other payables

 

 

 

(10,367

)

 

 

(13,356

)

Operating lease liabilities, current

 

 

 

(93

)

 

 

(89

)

Total current liabilities

 

 

 

(10,460

)

 

 

(13,613

)

Contract liabilities

 

 

 

(55,218

)

 

 

(55,454

)

Operating lease liabilities

 

 

 

(43

)

 

 

(71

)

Total liabilities

 

 

$

(65,721

)

 

$

(69,138

)

Commitments and contingencies (Note 11)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders’ equity

 

 

 

 

 

 

 

Ordinary shares – par value £0.05 per share; 141,703,840 shares issued at March 31, 2026 (December 31, 2025: 141,701,848)

 

 

 

(10,290

)

 

 

(10,290

)

Additional paid-in capital

 

 

 

(620,006

)

 

 

(617,562

)

Accumulated deficit

 

 

 

577,526

 

 

 

562,572

 

Accumulated other comprehensive loss

 

 

 

3,368

 

 

 

2,976

 

Total shareholders’ equity

 

 

 

(49,402

)

 

 

(62,304

)

 

 

 

 

 

 

 

 

Total liabilities and shareholders’ equity

 

 

$

(115,123

)

 

$

(131,442

)

 

Silence Therapeutics plc

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except share and per share data)

 

 

 

 

Three months ended March 31,

 

 

 

2026

 

2025

Revenue

 

 

$

422

 

 

$

142

 

Cost of sales

 

 

 

(11

)

 

 

(54

)

Gross profit

 

 

 

411

 

 

 

88

 

Research and development costs

 

 

 

(9,122

)

 

 

(20,813

)

General and administrative expenses

 

 

 

(7,026

)

 

 

(7,684

)

Operating loss

 

 

 

(15,737

)

 

 

(28,409

)

Foreign currency gain/(loss), net

 

 

 

(482)

 

 

 

(3,769

)

Other income, net

 

 

 

571

 

 

 

969

 

Benefit from R&D credit

 

 

 

691

 

 

 

2,679

 

Loss before income tax expense

 

 

 

(14,957

)

 

 

(28,530

)

Income tax expense

 

 

 

 

 

 

 

Net Loss

 

 

$

(14,957

)

 

$

(28,530

)

Loss per share (basic and diluted)

 

 

$

(0.11

)

 

$

(0.20

)

Weighted average shares outstanding (basic and diluted)

 

 

 

141,702,578

 

 

 

141,678,734

 

 

Inquiries:

Silence Therapeutics plc

Gem Hopkins, VP, IR and Corporate Communications

[email protected]

Tel: +1 (646) 637-3208

KEYWORDS: New York Europe United States United Kingdom North America

INDUSTRY KEYWORDS: Health Genetics Other Health Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

ClearBridge Energy Midstream Opportunity Fund Inc. Announces Unaudited Balance Sheet Information as of April 30, 2026

ClearBridge Energy Midstream Opportunity Fund Inc. Announces Unaudited Balance Sheet Information as of April 30, 2026

NEW YORK–(BUSINESS WIRE)–
ClearBridge Energy Midstream Opportunity Fund Inc. (NYSE: EMO) announced today the unaudited statement of assets and liabilities, the net asset value and asset coverage ratio of the Fund as of April 30, 2026.

As of April 30, 2026, the Fund’s net assets were $1,168.5 million, and its net asset value per share was $58.38. The Fund’s asset coverage ratio under the Investment Company Act of 1940 (the “1940 Act”) with respect to senior indebtedness was 723% and the Fund’s asset coverage ratio under the 1940 Act with respect to total leverage was 538%.

As of April 30, 2026
 

Amount (millions)

Per Share

 
Investments

$ 1,528.2

$ 76.35

 

Cash and Cash Equivalents

15.9

0.79

 

Other Assets

16.3

0.81

 

Total Assets

$ 1,560.4

$ 77.95

 

 
Senior Notes*

$ 14.5

$ 0.72

 

Loans Outstanding*

184.0

9.19

 

Mandatory Redeemable Preferred Shares*

68.2

3.41

 

Total Leverage

$ 266.7

$ 13.32

 

 
Deferred Tax Liability

$ 122.3

$ 6.11

 

Other Liabilities

2.9

0.14

 

Total Liabilities

$ 125.2

$ 6.25

 

 
Net Assets

$ 1,168.5

$ 58.38

 

 
Outstanding Shares

20,014,627

 
* The Fund’s asset coverage ratio under the 1940 Act with respect to senior indebtedness was 723%.
* The Fund’s asset coverage ratio under the 1940 Act with respect to total leverage was 538%.
 
Top Ten Equity Holdings (as of April 30, 2026)**
Market Value
Name (millions) % of Investments ***
Targa Resources Corp.

$ 184.7

12.1

%

Energy Transfer LP

$ 142.7

9.3

%

Williams Cos. Inc.

$ 128.1

8.4

%

MPLX LP

$ 109.5

7.2

%

ONEOK Inc.

$ 108.5

7.1

%

Kinder Morgan Inc.

$ 104.6

6.8

%

Western Midstream Partners LP

$ 101.4

6.6

%

Enterprise Products Partners LP

$ 92.0

6.0

%

Enbridge Inc.

$ 80.1

5.2

%

Antero Midstream Corp.

$ 72.2

4.7

%

$ 1,123.8

73.4

%

** Subject to change at any time
*** Percent of Total Equity Investments

ClearBridge Energy Midstream Opportunity Fund Inc. is a non-diversified, closed-end management investment company, which is advised by Franklin Templeton Fund Adviser, LLC (“FTFA”) and subadvised by ClearBridge Investments, LLC (“ClearBridge”). FTFA and ClearBridge are indirect, wholly-owned subsidiaries of Franklin Resources, Inc. (“Franklin Resources”).

This financial data is unaudited.

The Fund files its semi-annual and annual reports with the Securities and Exchange Commission (“SEC”), as well as its complete schedule of portfolio holdings for the first and third quarters of each fiscal year as an exhibit to its reports on Form N-PORT. These reports are available on the SEC’s website at www.sec.gov. To obtain information on Form N-PORT or a semi-annual or annual report from the Fund, shareholders can call 1-888-777-0102.

For more information about the Fund, please call 1-888-777-0102 or consult the Fund’s website at www.franklintempleton.com/investments/options/closed-end-funds. Hard copies of the Fund’s complete audited financial statements are available free of charge upon request.

Data and commentary provided in this press release are for informational purposes only. Franklin Resources and its affiliates do not engage in selling shares of the Fund.

Copyright © 2026. Franklin Templeton. All rights reserved.

Category: Financials

Source: Franklin Resources, Inc.

Source: Legg Mason Closed End Funds

Investor Contact: Fund Investor Services 1-888-777-0102        

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Business Other Professional Services Finance Asset Management Banking

MEDIA:

Aemetis Reports First Quarter 2026 Financial Results

Revenue Growth of 27%, Positive Gross Profit, and Increased Dairy RNG Production

  • Revenues of $54.6 million, an increase of 27% over Q1 2025, with growth across California Ethanol, Dairy RNG, and India Biodiesel segments
  • Gross profit of $2.8 million, compared with a gross loss of $5.1 million in Q1 2025
  • Operating loss improved approximately 60% to $6.3 million, compared with $15.6 million in Q1 2025
  • Aemetis Biogas RNG sales volume grew 55% to 110,000 MMBtu, compared with 71,000 MMBtu in Q1 2025
  • India Biodiesel rebounded to $10.5 million in revenue with the resumption of OMC tender shipments under new contracts
  • $4.0 million of Section 45Z Production Tax Credits recognized in Q1 2026 — representing the first quarter of ongoing credits generation tied to quarterly production since 45Z eligibility was established in Q4 2025
  • Revenues include LCFS credits earned from seven Dairy RNG pathways with an average CI score of negative 380, versus the negative 150 default pathway that applied for Q1 2025 revenues — with 6 additional biogas pathways nearing approval
  • First delivery of four dairy biogas pretreatment skids in April under $27 million fabrication contract
  • First delivery of major equipment to Keyes ethanol plant for $40 million Mechanical Vapor Recompression system
  • First delivery of major equipment for on-site RNG station to directly fuel trucks and gas delivery trailers without using utility gas pipeline

CUPERTINO, Calif., May 07, 2026 (GLOBE NEWSWIRE) — Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on lower-cost and lower-emission products, today announced its financial results for the three months ended March 31, 2026.

“Revenues during the first quarter of 2026 were $54.6 million, reflecting strong execution across our California Ethanol, Dairy RNG, and India Biodiesel segments, with each segment contributing to a 27% year-over-year revenue increase, ” said Todd Waltz, Chief Financial Officer of Aemetis.  “We posted gross profit of $2.8 million in the quarter compared with a gross loss in the same quarter last year, reflecting both operational scale and the generation of Section 45Z Production Tax Credits. With seven fully approved LCFS provisional pathways averaging a negative 380 CI score, and six more biogas pathways nearing approval, we expect to significantly improve our Low Carbon Fuel Standard revenues during later quarters of 2026.”

“We are pleased with the continued growth of Aemetis Biogas production, including the ramp up of volumes from a large centralized dairy digester to process waste from multiple dairies that became operational late last year,” said Eric McAfee, Chairman and CEO of Aemetis.  “Our focus on significantly improving cash flow from our California Ethanol segment is underway with the delivery of major equipment for the mechanical vapor recompression project, which uses on-site solar and local geothermal grid electricity to displace approximately 80% of the fossil natural gas at Keyes. The India Biodiesel subsidiary continues to lead the industry during a time of rapid growth and a renewed focus by the India government.”
  
Today, Aemetis will host an earnings review call at 11:00 a.m. Pacific time (PT).

Live Participant Dial In (Toll Free): +1-888-506-0062 entry code 943189
Live Participant Dial In (International): +1-973-528-0011 entry code 943189
Webcast URLhttps://www.webcaster5.com/Webcast/Page/2211/53904

For details on the call, please visit http://www.aemetis.com/investors/conference-calls/

Financial Results for the Three Months Ended March 31, 2026

Revenues were $54.6 million during the first quarter of 2026, an increase from $42.9 million for the first quarter of 2025. Dairy RNG segment sold 110,000 MMBtu during the first quarter, an increase of 55% from 71,000 MMBtu during the same period of the prior year. The ethanol gallons sold were slightly lower at 13.7 million gallons during the first quarter of 2026 compared to 14.1 million gallons during the first quarter of 2025. Average ethanol selling price remained constant during the two periods. Biodiesel sales rose to $10.5 million during the first quarter of 2026 with the resumption of biodiesel tender orders. Tax credits related to 45Z were recognized as revenue of $1.4 million and $2.6 million in Dairy RNG and California Ethanol segments respectively.

Gross profit for the first quarter of 2026 was $2.8 million, compared to a gross loss of $5.1 million during the first quarter of 2025 reflecting improved profitability in the California Ethanol segment and improved profitability in the Dairy RNG segment from increased RNG production and the seven approved LCFS provisional pathways.

Selling, general and administrative expenses decreased by $1.4 million to $9.1 million during the first quarter of 2026 compared to $10.5 million during the same period in 2025, driven primarily from legal and other transaction costs associated with investment tax credit sales during the first quarter of 2025.

Operating loss was $6.3 million for the first quarter of 2026, compared to operating loss of $15.6 million for the same period in 2025.

Interest expense, excluding accretion of Series A preferred units in the Aemetis Biogas LLC subsidiary, increased to $14.4 million during the first quarter of 2026 compared to $13.7 million during the first quarter of 2025. Additionally, Aemetis Biogas recognized $1.6 million of accretion of Series A preferred units during the first quarter of 2026 compared to $2.3 million during the first quarter of 2025.

Net loss was $21.7 million for the first quarter of 2026, compared to net loss of $24.5 million for the first quarter of 2025.

Adjusted EBITDA for the first quarter of 2026 was negative $1.3 million, compared with negative $10.7 million in the first quarter of 2025. A reconciliation of Adjusted EBITDA to net loss is included in the supplemental tables that follow.

Cash at the end of the first quarter of 2026 was $4.8 million compared to $4.9 million at the close of the fourth quarter of 2025. Investments in capital projects related to carbon intensity reductions at the Keyes ethanol plant and construction of dairy digesters of $6.5 million for the first quarter of 2026 was a significant increase over $1.8 million during the first quarter of 2025.

Section 45Z Production Tax Credits

During 2025, Aemetis recognized $10.4 million of Section 45Z Production Tax Credit operating income, comprised of $5.2 million in the Dairy RNG segment and $5.1 million in the California Ethanol segment. As disclosed in the Company’s 2025 Form 10-K, this full-year recognition was reflected in the fourth quarter of 2025, when eligibility and transferability requirements were demonstrated. First quarter 2026 results reflect $4.0 million of Section 45Z Production Tax Credit revenue based upon credits earned from first quarter production of ethanol and RNG — $1.4 million in Dairy RNG and $2.6 million in California Ethanol. As a result, first quarter 2026 California Ethanol and Dairy RNG revenues are expected to reflect underlying production economics comparable to the fourth quarter of 2025 on a basis that excludes the full-year 45Z recognition booked in that quarter. The Company expects 45Z accrual and monetization timing to normalize on a quarterly cadence going forward, with further improvement pending publication of the updated 45ZCF-GREET model by the Department of Energy.

Capital Structure and Financing Update

The Company is pursuing a multi-track financing plan to address near-term obligations and fund continued growth across its operating platform. Financing initiatives currently underway include advanced preparation for a potential long-term financing of the Keyes ethanol plant; ongoing financing efforts to support the continued Dairy RNG digester buildout; and continued progress toward a planned initial public offering of the Company’s India subsidiary, Universal Biofuels Private Limited, for which the Company has retained legal, accounting, and IPO advisors and expects to provide an update on investment banking engagement in the near term. The MVR upgrade at Keyes is on track for 2026 completion.

About Aemetis

Headquartered in Cupertino, California, Aemetis is a diversified renewable natural gas and biofuels company focused on the development and operation of innovative technologies that lower energy costs and reduce emissions. Founded in 2006, Aemetis is operating and expanding a California biogas digester network and pipeline system to convert dairy waste gas into Renewable Natural Gas. Aemetis owns and operates a 65 million gallon per year ethanol production facility in California’s Central Valley near Modesto that supplies about 80 dairies with animal feed. Aemetis owns and operates an 80 million gallon per year production facility on the East Coast of India producing high quality biodiesel and refined glycerin. To utilize the byproducts from ethanol production, Aemetis is developing a sustainable aviation fuel plant and a CO2 sequestration project in California. For additional information about Aemetis, please visit www.aemetis.com.

Non-GAAP Financial Information

We have provided non-GAAP measures as a supplement to financial results based on GAAP. A reconciliation of the non-GAAP measures to the most directly comparable GAAP measures is included in the accompanying supplemental data. Adjusted EBITDA is defined as net income/(loss) plus (to the extent deducted in calculating such net income) interest and amortization expense, bad debt expense, income tax expense or benefit, accretion of Series A preferred unit expense, stock issued for services, monetized investment tax credits, loss on sale of assets, depreciation and amortization expense, and share-based compensation expense.

Adjusted EBITDA is not calculated in accordance with GAAP and should not be considered as an alternative to net income/(loss), operating income or any other performance measures derived in accordance with GAAP or to cash flows from operating, investing or financing activities as an indicator of cash flows or as a measure of liquidity. Adjusted EBITDA is presented solely as a supplemental disclosure because management believes that it is a useful performance measure that is widely used within the industry in which we operate. In addition, management uses Adjusted EBITDA for reviewing financial results, budgeting, and planning purposes. EBITDA measures are not calculated in the same manner by all companies and, accordingly, may not be an appropriate measure for comparison between companies.

Safe Harbor Statement

This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions, or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, statements relating to our five-year growth plan; trends in market conditions with respect to prices for inputs for our products versus prices for our products; our ability to fund, develop, build, maintain and operate digesters, facilities and pipelines for our Dairy Renewable Natural Gas segment; our ability to fund, develop and operate our Sustainable Aviation Fuel, Renewable Diesel, and Carbon Capture and Sequestration projects, including obtaining required permits; our ability to refinance existing debt; our intention to repurchase the Series A preferred units relating to our Aemetis Biogas subsidiary; and our ability to raise additional equity capital or debt. Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “showing signs,” “targets,” “view,” “will likely result,” “will continue” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, and other risks detailed in our reports filed with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and other filed documents. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.

Company Investor Relations/

Media
Contact:

Todd Waltz
(408) 213-0940
[email protected]

External Investor Relations Contact:

Kirin Smith
PCG Advisory Group
(646) 863-6519
[email protected] 

(Tables follow)

AEMETIS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share data)
               
        For the three months ended
March 31,
 
          2026       2025    
               
Revenues   $ 54,619     $ 42,886    
Cost of goods sold     51,863       47,966    
Gross profit (loss)     2,756       (5,080 )  
               
Selling, general and administrative expenses     9,091       10,475    
Operating loss     (6,335 )     (15,555 )  
               
Other expense (income):          
  Interest expense          
    Interest rate expense     12,403       11,018    
    Debt related fees and amortization expense   1,971       2,675    
    Accretion and other expenses of Series A preferred units   1,613       2,279    
  Total interest expense     15,987       15,972    
  Other income     (478 )     (215 )  
Other expense (income), net     15,509       15,757    
               
Loss before income taxes     (21,844 )     (31,312 )  
  Income tax benefit     (131 )     (6,783 )  
Net loss   $ (21,713 )   $ (24,529 )  
               
Net loss per common share          
  Basic   $ (0.33 )   $ (0.47 )  
  Diluted   $ (0.33 )   $ (0.47 )  
               
Weighted average shares outstanding          
  Basic     66,802       52,584    
  Diluted     66,802       52,584    
               
         
AEMETIS, INC.    
CONSOLIDATED CONDENSED BALANCE SHEETS    
(in thousands)    
                     
          March 31, 2026   December 31, 2025  
          (Unaudited)          
Assets                  
  Current assets:                
    Cash and cash equivalents     $ 4,797     $ 4,894        
    Accounts receivable     6,584       484        
    Inventories       10,384       11,627        
    Prepaid and other current assets       12,922       9,867        
  Total current assets       34,687       26,872        
                     
    Property, plant and equipment, net       222,743       219,717        
    Other assets       12,899       13,252        
  Total assets     $ 270,329     $ 259,841        
                     
Liabilities and stockholders’ deficit                
  Current liabilities:                
    Accounts payable     $ 23,719     $ 23,418        
    Current portion of long term debt       293,828       279,143        
    Short term borrowings     48,802       38,726        
    Other current liabilities       29,897       29,971        
  Total current liabilities       396,246       371,258        
                     
  Total long term liabilities       195,221       195,414        
                     
  Stockholders’ deficit:                
    Common stock     69       66        
    Additional paid-in capital       348,741       340,402        
    Accumulated deficit     (661,656 )     (639,943 )      
    Accumulated other comprehensive loss       (8,292 )     (7,356 )      
  Total stockholders’ deficit       (321,138 )     (306,831 )      
Total liabilities and stockholders’ deficit     $ 270,329     $ 259,841        
                 
AEMETIS, INC.  
RECONCILIATION OF ADJUSTED EBITDA TO NET INCOME/(LOSS)  
(unaudited, in thousands)  
               
      For the three months ended
March 31,
   
  EBITDA Calculation   2026       2025      
               
  Net loss $ (21,713 )   $ (24,529 )    
  Adjustments          
    Interest and amortization expense   14,374       13,705      
    Depreciation and amortization expense   2,535       2,357      
    Accretion of Series A preferred units   1,613       2,279      
    Share-based compensation   1,704       2,308      
    Stock issued for services   50            
    Monetized investment tax credits         (7,075 )    
    Bad debt Expense   276            
    Loss on sale of assets   2            
    Income tax expense or (benefit)   (131 )     292      
  Total adjustments   20,423       13,866      
               
  Adjusted EBITDA $ (1,290 )   $ (10,663 )    
               
               
AEMETIS, INC.
PRODUCTION AND PRICE PERFORMANCE
(unaudited)
           
  Three Months ended
March 31,
 
    2026     2025    
           
California Ethanol          
Ethanol          
Gallons sold (in millions)   13.7     14.1    
Average sales price/gallon   1.97     1.98    
Percent of nameplate capacity   100 %   103 %  
WDG          
Tons sold (in thousands)   91     93    
Average sales price/ton $ 84   $ 86    
Delivered Cost of Corn          
Bushels ground (in millions)   4.7     4.8    
Average delivered cost / bushel $ 5.93   $ 6.63    
           
           
California Dairy Renewable Natural Gas          
Renewable Natural Gas          
MMBtu sold (in thousands)   110     71    
Average price per MMBtu $ 1.98   $ 3.65    
RINs          
RINs sold (in thousands)   801     388    
Average price per RIN $ 2.41   $ 2.64    
LCFS          
LCFS credits sold (in thousands)   30     16    
Average price per LCFS credit $ 55.00   $ 72.50    
           
India Biodiesel          
Biodiesel          
Metric tons sold (in thousands)   9.2        
Average Sales Price/Metric ton $ 1,037   $    
Percent of Nameplate Capacity   24.5 %      
Refined Glycerin          
Metric tons sold (in thousands)   0.8        
Average Sales Price/Metric ton $ 1,257   $    
           



Redfin Reports Pending Home Sales Hit Highest Level in Nearly 4 Years

Redfin Reports Pending Home Sales Hit Highest Level in Nearly 4 Years

More homebuyers jumped into the market as mortgage rates came down temporarily last week, but it’s still slower than past springs

SEATTLE–(BUSINESS WIRE)–
U.S. pending home sales hit their highest level since September 2022 during the four weeks ending May 3, according to a new report from Redfin, the real estate brokerage powered by Rocket. They rose 7.7% year over year on a seasonally adjusted basis.

There are a few reasons homebuyers are coming off the sidelines:

  • Housing costs came down temporarily. The median U.S. housing payment declined 2.2% year over year as mortgage rates ticked down. Rates fell to 6.23% last week from a 6-month high of 6.46% two weeks earlier. (Dailyaverage rates rose as high as 6.56% this week due to jitters about renewed fighting and uncertainty in Iran.)
  • There are more houses on the market. The total number of homes for sale rose roughly 1% year over year to near their highest level in at least five years. When there are more homes to buy, there are more sales.
  • Seasonality is kicking in later than usual. Spring is typically the busiest time of year for the housing market: A recent Redfin analysis found that late April is the best time of year to list a home for sale because homes are more likely to sell above their asking price, and to sell quickly. The big uptick in seasonally adjusted pending sales could signal that spring homebuying season is starting late.

Still, the market is slower and less competitive than past springs. The typical home that sells goes under contract in 43 days, three days longer than a year ago. Just over one-quarter (26.4%) of homes that go under contract are selling above asking price, the lowest share for this time of year in at least five years.

“Some homes are attracting multiple offers, but only those that are priced fairly and have been updated,” said Ashley Arzer, a Redfin Premier agent in Chicago. “A new kitchen and new bathroom are the ticket to a bidding war. Older homes that need repairs, and those far above the most popular price range—around $400,000 in Chicago—are taking longer to sell.”

For Redfin economists’ takes on the housing market, please visit Redfin’s “From Our Economists” page.

Leading indicators

Indicators of homebuying demand and activity

 

Value (if applicable)

Recent change

Year-over-year change

Source

Daily average 30-year fixed mortgage rate

6.44% (May 6)

Down from 6.56% on May 4, which was the highest level since end of March

Down from 6.9%

Mortgage News Daily

Weekly average 30-year fixed mortgage rate

6.3% (week ending April 30)

Up from 6.23% one week earlier

Down from 6.76%

Freddie Mac

Mortgage-purchase applications (seasonally adjusted)

 

Down 4% from a week earlier (as of week ending May 1)

Up 5%

Mortgage Bankers Association

Google searches of “homes for sale”

 

Highest level in 9 months (as of May 4)

Up more than 20%

Google Trends

Touring activity

 

Up 32% from the start of the year (as of May 4)

At this time last year, it was up 43% from the start of 2025

ShowingTime

Key housing-market data

U.S. highlights: Four weeks ending May 3, 2026

Redfin’s national metrics include data from 900+ U.S. metro areas and are based on homes listed and/or sold during the period. Weekly housing-market data goes back through 2021. Subject to revision.

 

Four weeks ending

May 3, 2026

Year-over-year change

Notes

Median sale price

$394,803

1.9%

 

Median asking price (seasonally adjusted)

$406,493

1.5%

 

Median monthly mortgage payment (seasonally adjusted)

$2,606 at a 6.3% mortgage rate

-2.2%

 

Pending sales (seasonally adjusted)

340,101

7.7%

 

New listings (seasonally adjusted)

373,607

-1.8%

 

Active listings (seasonally adjusted)

1,477,250

0.9%

 

Months of supply

3.5

-0.1 pts.

4 to 5 months of supply is considered balanced, with a lower number indicating seller’s market conditions

Share of homes off market in two weeks

39.2%

Down from 40%

 

Median days on market

43

+3 days

 

Share of home listings with price drops

18.8%

Essentially unchanged

 

Share of homes sold above list price

26.4%

Down from 28%

 

Average sale-to-list price ratio

98.7%

Down from 99%

 

Metro-level highlights: Four weeks ending May 3, 2026

Redfin’s metro-level data includes the 50 most populous U.S. metros. Select metros may be excluded from time to time to ensure data accuracy.

 

Metros with biggest year-over-year increases

Metros with biggest year-over-year decreases

Notes

Median sale price

San Francisco (11%)

Cleveland (8.2%)

Kansas City, MO (7.9%)

Cincinnati (7.5%)

Detroit (7.4%)

Newark, NJ (-3.3%)

San Jose, CA (-3.2%)

Seattle (-3.2%)

Dallas (-3.2%)

Las Vegas (-2.5%)

Declined in 19 metros

Pending sales

Chicago (19.2%)

Pittsburgh (16.5%)

San Francisco (15.2%)

Miami (15%)

Austin, TX (14.6%)

Houston (-9.3%)

Detroit (-3.3%)

Seattle (-2.7%)

Warren, MI (-1.8%)

Declined in just 4 metros

New listings

Columbus, OH (9.5%)

Nassau County, NY (9.4%)

Cincinnati (9.2%)

Milwaukee (9.1%)

Newark, NJ (9.1%)

Dallas (-14.9%)

Jacksonville, FL (-14.5%)

Denver (-14.3%)

Fort Worth, TX (-13%)

Las Vegas (-13%)

 

 

 

To view the full report, including charts, please visit: https://www.redfin.com/news/pending-home-sales-rise-spring

About Redfin

Redfin is a technology-driven real estate company with the country’s most-visited real estate brokerage website. As part of Rocket Companies (NYSE: RKT), Redfin is creating an integrated homeownership platform from search to close to make the dream of homeownership more affordable and accessible for everyone. Redfin’s clients can see homes first with on-demand tours, easily apply for a home loan with Rocket Mortgage, and save thousands in fees while working with a top local agent.

You can find more information about Redfin and get the latest housing market data and research at https://www.redfin.com/news. For more information about Rocket Companies, visit https://www.rocketcompanies.com.

Contact Redfin Journalist Services:

Kynsay Hunt

[email protected]

KEYWORDS: Washington United States North America

INDUSTRY KEYWORDS: Professional Services Data Analytics Technology Residential Building & Real Estate Software Construction & Property Banking

MEDIA:

Logo
Logo

The Hartford’s Study: Amid Rising Cost Of Living, AI Emerging As Benefits Decision-Making Tool For Gen Z

The Hartford’s Study: Amid Rising Cost Of Living, AI Emerging As Benefits Decision-Making Tool For Gen Z

HARTFORD, Conn.–(BUSINESS WIRE)–
AI search tools are now a part of how of some U.S. workers are making employee benefits decisions, particularly as inflation is driving up the cost of living, according to the Future of Benefits Study from The Hartford, a leading provider of employee benefits and absence management.

The study found that 43% of U.S. workers are never sure they are choosing the right benefits – uncertainty that is driving a younger subset to seek guidance from AI search tools such as ChatGPT. Overall, 17% of U.S. workers used AI to help with benefits decisions during open enrollment. However, more than half of those workers were Gen Z. While younger workers express growing unease about AI’s broader impact on work and creativity according to a recent Gallup poll, Gen Z acknowledges AI’s relevance and is curious about it.

“American workers are getting benefits information from more sources than ever before – HR portals, colleague and peer advice, and now AI,” said Mike Fish, head of Employee Benefits at The Hartford. “Regardless of how they prefer to receive their information, we help our employer clients provide support that’s easy to access using AI-backed tools and clear, simple benefits communication.”

Key Findings on AI and Benefits Enrollment:

  • 94% of Gen Z workers who said they used AI (such as ChatGPT) during enrollment trusted the recommendations it provided; and

  • Among U.S. workers who used AI during benefits enrollment, they reported using it to:

    • Compare different benefits options (59%);

    • Get general information about benefits (55%);

    • Get personalized recommendations (51%);

    • Calculate costs or estimate expenses (45%); and

    • Have someone tell them exactly what to choose or buy (31%).

In addition to the emerging use of AI for benefits guidance, the study shows U.S. workers are grappling with the financial pressures of everyday living expenses. Half of U.S. workers say they are unsure if they will have enough money for future medical care. As premiums, deductibles and everyday living expenses rise, employees are taking a closer look at supplemental health benefits – such as accident, critical illness and hospital indemnity insurance – as a way to gain access to added financial protection to help manage everyday expenses.

Key Findings on Cost of Living:

  • 44% of U.S. workers say they are more worried about daily expenses – such as food, housing, healthcare and unexpected costs – than they are about their long-term financial future;

  • 38% of respondents say their financial situation is affecting their mental health;

  • 73% of blue-collar workers say they consider supplemental health benefits a part of their overall financial plan, compared with 60% of white-collar workers, and 54% of service-based workers, such as wait staff, salespeople, retail clerks, non-professional healthcare workers; and

  • Top reasons that U.S. workers enrolled in supplemental health benefits were:

    • To have peace of mind for unexpected health events (62%);

    • To help cover out of pocket costs (48%); and

    • To fill gaps in medical and/or pharmacy coverage (37%).

“U.S. workers want benefits that can help protect their paychecks – not just in a worst-case scenario, but in everyday life,” said Fish. “These findings reinforce why clear, easy-to-use guidance, backed by knowledgeable support, matters more than ever as people weigh their options and look for coverage that helps close gaps and manage daily expenses.”

Methodology:

The Hartford’s 2026 Future of Benefits Study of 1,000 U.S. workers was fielded between Dec. 3 through Dec. 11, 2025. The U.S. workers surveyed were actively employed. The margin of error for U.S. workers is +/-4% at a 95% confidence level.

About The Hartford

The Hartford is a leader in property and casualty insurance, employee benefits and mutual funds. With more than 200 years of expertise, The Hartford is widely recognized for its service excellence, sustainability practices, trust and integrity. More information on the company and its financial performance is available at https://www.thehartford.com.

The Hartford Insurance Group, Inc., (NYSE: HIG) operates through its subsidiaries under the brand name, The Hartford, and is headquartered in Hartford, Connecticut. For additional details, please read The Hartford’s legal notice.

HIG-E

Some of the statements in this release may be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results may differ materially. Investors should consider the important risks and uncertainties that may cause actual results to differ. These important risks and uncertainties include those discussed in our 2025 Annual Report on Form 10-K, subsequent Quarterly Reports on Forms 10-Q, and the other filings we make with the Securities and Exchange Commission. We assume no obligation to update this release, which speaks as of the date issued.

From time to time, The Hartford may use its website and/or social media channels to disseminate material company information. Financial and other important information regarding The Hartford is routinely accessible through and posted on our website at https://ir.thehartford.com. In addition, you may automatically receive email alerts and other information about The Hartford when you enroll your email address by visiting the “Email Alerts” section at https://ir.thehartford.com.

Media:

Sperry Mylott

860-547-4855

[email protected]

KEYWORDS: Connecticut United States North America

INDUSTRY KEYWORDS: Professional Services Consumer Technology Insurance Human Resources Artificial Intelligence Generation Z

MEDIA:

Logo
Logo

AIR Announces Plans to Open New Manufacturing Facility in Romania

AIR Announces Plans to Open New Manufacturing Facility in Romania

Expected to open by Q1 2027, the new facility will represent AIR’s ninth global facility and will boost its resilience to global geopolitical conditions

DUBAI, United Arab Emirates–(BUSINESS WIRE)–AIR Limited (“AIR” or the “Company”), the global leader in flavored shisha molasses and pioneer in advanced inhalation technologies, today announced plans to open a new approximately 70,000-square-foot manufacturing facility in Romania, located in Stefanesti, Bucharest North. The facility is expected to commence operations by Q1 2027.

Once fully operational, AIR expects to support more than 150 high-quality jobs at the facility, which is expected to be capable of producing more than 4,000 tons of flavored shisha molasses each year. This new facility would extend AIR’s operational capacity and flexibility in an increasingly uncertain global geopolitical environment.

“This new facility represents our continued momentum and a strategic advancement as we fortify our position as the global market leader in social inhalation products,” said Stuart Brazier, CEO of AIR. “As we expand our global footprint and move towards a public market listing, this facility will enhance our production capabilities and provide added operational resilience in the context of a more uncertain global geopolitical context. It’s exactly the type of strategic direction that supports long-term operational strength and supply chain flexibility for our growing line of products.”

AIR’s financial performance reflects the company’s strong market position and growth trajectory. In 2025, the company achieved revenues of approximately $400 million, representing 6% year-over-year growth, while EBITDA grew 8% to $139 million. The company has demonstrated particular strength in Western markets, including the United States, Germany and Spain, in which our sales grew at an approximate 14% CAGR from 2020 to 2025.

Background Information on AIR’s Business Combination

On November 7, 2025, AIR and CAEP announced that they entered into a definitive business combination agreement (the “Business Combination”) that, upon closing, is intended to result in the combined company AIR Global PLC (“AIR Global”) becoming publicly listed on the Nasdaq in the United States under the ticker symbol “AIIR.”

The transaction is expected to be completed in the second quarter of 2026, subject to regulatory approvals and other customary conditions. Additional information about the Business Combination, including a copy of the Business Combination Agreement, are available in a Current Report on Form 8-K filed by CAEP with the SEC on November 7, 2025 and the definitive proxy statement filed by CAEP and the Registration Statement filed by the Company and AIR Holdings Limited with the SEC, each dated April 22, 2026 and all available at www.sec.gov.

About AIR

Launched in 1999 and headquartered in Dubai, AIR is a global innovation leader in social inhalation, with a multinational presence in over 90 markets worldwide. Its portfolio of companies and assets includes Al Fakher, the world’s leading flavored shisha molasses brand; Hookah.com, North America’s number one B2B e-commerce platform for hookah and shisha by market share; and OOKA, a highly innovative charcoal-free shisha device, among others. AIR’s science program, conducted in partnership with independent accredited laboratories, enables the development of innovative products that combine centuries of tradition with cutting-edge technology designed to reduce harmful compounds and maximize enjoyment for millions around the world.

For more information, please visit https://air.global/.

About Cantor Equity Partners III, Inc.

Cantor Equity Partners III, Inc. (Nasdaq: CAEP) is a special purpose acquisition company sponsored by an affiliate of Cantor Fitzgerald and led by Chairman and Chief Executive Officer Brandon Lutnick. Cantor Equity Partners III, Inc. was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

About Cantor Fitzgerald, L.P.

Cantor Fitzgerald, with nearly 16,000 employees, is a leading global financial services and real estate services holding company and a proven and resilient leader for more than 81 years. Its diverse group of global companies provides a wide range of products and services, including investment banking, asset and investment management, capital markets, prime services, research, digital assets, data, financial and commodities brokerage, trade execution, clearing, settlement, advisory, financial technology, custodial, commercial real estate advisory and servicing, and more.

Forward-Looking Statements

This press release contains “forward-looking statements,” within the meaning of U.S. federal securities laws. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “opportunity,” “plan,” “project,” “should,” “strategy,” “will,” “will be,” “will continue,” “will likely result,” “would” and similar expressions (including the negative versions of such words or expressions).

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to, among other things, the anticipated timing and completion of the Proposed Business Combination; AIR Global’s proposed Nasdaq listing; the ability to satisfy closing conditions, obtain required shareholder and regulatory approvals, and meet applicable listing standards; the expected structure of the Proposed Business Combination and potential adjustments thereto; anticipated benefits of the Proposed Business Combination to AIR, CAEP and AIR Global; AIR’s growth strategy, market expansion plans, product innovation pipeline and commercialization efforts (including with respect to OOKA and other new technologies); partnerships and go-to-market initiatives; and market size, share and adoption trends. These statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause AIR Global’s or AIR’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the occurrence of any event, change or other circumstances that could give rise to the termination of the Proposed Business Combination (including as a result of a termination of the Business Combination Agreement and/or any related agreements between the relevant parties); the outcome of any legal proceedings that may be instituted against AIR Global, CAEP or AIR, any of their subsidiaries or others following the announcement of the Proposed Business Combination; the inability to complete the Proposed Business Combination due to the failure to obtain the necessary shareholder approvals or to satisfy other conditions to closing; changes to the proposed structure of the Proposed Business Combination that may be required or appropriate as a result of applicable laws or regulations; the ability to meet the Nasdaq Stock Market listing standards upon closing of the Proposed Business Combination and admission of AIR Global for trading on the Nasdaq Stock Market; the risk that the Proposed Business Combination disrupts current plans and operations of AIR as a result of the announcement and consummation of the Proposed Business Combination; the ability to recognize the anticipated benefits of the Proposed Business Combination, which may be affected by, among other things, competition, the ability of AIR to grow, retain its management and key employees; costs related to the Proposed Business Combination; changes in applicable laws or regulations; and other risks and uncertainties set forth in the F-4. Forward-looking statements are inherently subject to risks and uncertainties, many of which AIR, CAEP and AIR Global cannot predict with accuracy and some of which neither AIR, CAEP nor AIR Global might even anticipate. The forward-looking statements contained in this press release speak only as of the date of this release. Readers are cautioned not to put undue reliance on forward-looking statements, and AIR, CAEP and AIR Global do not assume any obligation to and do not intend to publicly update any forward-looking statement to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events, except as required by U.S. federal securities laws. The inclusion of any statement in this communication does not constitute an admission by CAEP, AIR or AIR Global or any other person that the events or circumstances described in such statement are material.

No assurances can be made that the parties will successfully close the Proposed Business Combination or close the Proposed Business Combination on the timeframe currently contemplated. The Proposed Business Combination is subject to regulatory approvals and other customary conditions to closing.

The foregoing list of risk factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the definitive proxy statement filed by CAEP and the final prospectus filed by AIR Global, each dated April 22, 2026, the final prospectus of CAEP dated as of June 25, 2025 and filed by CAEP with the SEC on June 26, 2025, CAEP’s Quarterly Reports on Form 10-Q, CAEP’s Annual Report on Form 10-K, and other documents filed by CAEP and AIR Global from time to time with the SEC. These filings do or will identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. There may be additional risks that CAEP, AIR and AIR Global do not presently know or that CAEP, AIR and AIR Global currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements.

Important Information for Investors and Shareholders

AIR Global and AIR initially filed an F-4 registration statement with the SEC on April 22, 2026 (the “F-4”), which became effective on April 22, 2026 and contains a definitive proxy statement of CAEP and a final prospectus of AIR Global in connection with the Proposed Business Combination. The definitive proxy statement and other relevant documents will be mailed to shareholders of CAEP as of the record date of April 17, 2026. SHAREHOLDERS OF CAEP AND OTHER INTERESTED PARTIES ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN CONNECTION WITH CAEP’S SOLICITATION OF PROXIES FOR THE EXTRAORDINARY GENERAL MEETING OF ITS SHAREHOLDERS TO BE HELD TO APPROVE THE PROPOSED BUSINESS COMBINATION BECAUSE THESE DOCUMENTS CONTAIN IMPORTANT INFORMATION ABOUT CAEP, AIR, AIR GLOBAL AND THE PROPOSED BUSINESS COMBINATION. Shareholders will also be able to obtain copies of the F-4 and the final proxy statement/prospectus, without charge, on the SEC’s website at www.sec.gov or by directing a request to Cantor Equity Partners III, Inc., 110 East 59th Street, New York, NY 10022, email: [email protected] and to AIR Global, Festival Office Tower, Dubai Festival City, 7th Floor, Dubai, United Arab Emirates, email: [email protected].

Participants in the Solicitation

CAEP, AIR, AIR Global and their respective directors and executive officers and certain of their shareholders may be deemed under SEC rules to be participants in the solicitation of proxies of CAEP shareholders in connection with the Proposed Business Combination. A list of the names of such persons, and information regarding their interests in the Proposed Business Combination and their ownership of CAEP’s securities are contained in the F-4 as well as CAEP’s filings with the SEC, including CAEP’s prospectus filed on June 26, 2025. Additional information regarding the interests of the persons who may, under SEC rules, be deemed participants in the solicitation of proxies from CAEP’s shareholders in connection with the Proposed Business Combination, including the names and interests of CAEP’s, AIR Global’s and AIR’s directors and executive officers, are set forth in the proxy statement/prospectus contained in the F-4. Investors and security holders may obtain free copies of these documents as described above.

No Offer or Solicitation

This press release and the information contained herein are for informational purposes only and shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the Proposed Business Combination or an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”). Investors should consult with their counsel as to the applicable requirements for a purchaser to avail itself of any exemption under the Securities Act.

Investor and Media Relations:

ICR for AIR

[email protected]

KEYWORDS: Europe Romania United Arab Emirates Middle East

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Other Manufacturing Tobacco Technology Manufacturing Retail Other Technology

MEDIA:

Logo
Logo

Zscaler to Host Third Quarter Fiscal Year 2026 Earnings Conference Call

Earnings Results to be Released on Tuesday, May 26, After the Close of the Market

SAN JOSE, Calif., May 07, 2026 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, will release third quarter fiscal year 2026 earnings after the market closes on Tuesday, May 26, 2026. The company will host an investor conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the results.

Date:   Tuesday, May 26, 2026
Time:   1:30 p.m. PT
Webcast:   A live webcast of the conference call will be accessible from the Zscaler website at https://ir.zscaler.com. Listeners may log on to the call under the “Events & Presentations” section and select “Q3 2026 Zscaler Earnings Conference Call” to participate. 
Dial-in:   To join by phone, register at the following link: Click Here. After registering, you will be provided with a dial-in number and a personal PIN that you will need to join the call.


Please dial in at least 10 minutes prior to the 1:30 p.m. PT start time.

About Zscaler

Zscaler (NASDAQ: ZS) is a pioneer and global leader in zero trust security. The world’s largest businesses, critical infrastructure organizations, and government agencies rely on Zscaler to secure users, branches, applications, data & devices, and to accelerate digital transformation initiatives. Distributed across more than 160 data centers globally, the Zscaler Zero Trust Exchange™ platform combined with advanced AI combats billions of cyber threats and policy violations every day and unlocks productivity gains for modern enterprises by reducing costs and complexity.

Zscaler™ and the other trademarks listed at

https://www.zscaler.com/legal/trademarks

are either (i) registered trademarks or service marks or (ii) trademarks or service marks of Zscaler, Inc. in the United States and/or other countries. Any other trademarks are the properties of their respective owners.

Media Relations Contact:

Pavel Radda
[email protected]

Investor Relations Contact:

Kim Watkins
[email protected]